PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that its lead DNA medicine candidate, INO-3107, has been granted an Innovation Passport by the U.K.’s Innovative Licensing and Access Pathway (ILAP). The designation recognizes the potential of INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease of the respiratory tract caused by HPV-6 and HPV-11.
The Innovation Passport is a significant step for INO-3107, offering enhanced access to regulatory support and development tools. This could accelerate the timeline for achieving regulatory approval in the U.K., according to Dr. Jacqueline Shea, INOVIO’s President and CEO. “The U.K. Innovation Passport designation is yet another recognition of the promise of INO-3107 to potentially transform the treatment paradigm for RRP patients,” Dr. Shea said.
Recurrent Respiratory Papillomatosis is a debilitating ailment that affects the respiratory tract, leading to growths in the airways that can cause significant breathing difficulties. Current treatments are limited, often requiring repeated surgeries to remove the growths.
INO-3107 aims to offer a new approach by leveraging DNA medicine technology to target and treat the underlying causes of RRP. This innovative treatment has shown promise in early trials, positioning it as a potential game-changer for those afflicted with the disease.
The ILAP designation not only highlights the potential impact of INO-3107 but also facilitates closer collaboration with U.K. regulators. This cooperation could expedite the process of bringing the treatment to market, providing hope for patients who currently have limited options.
With this designation, INO-3107 is poised to move more rapidly through the regulatory process, potentially bringing relief to RRP patients sooner than previously anticipated.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.